NASDAQ:OPRX OptimizeRx (OPRX) Stock Price, News & Analysis $17.03 +0.89 (+5.51%) As of 01:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About OptimizeRx Stock (NASDAQ:OPRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get OptimizeRx alerts:Sign Up Key Stats Today's Range$15.97▼$16.8750-Day Range$12.48▼$17.5952-Week Range$3.78▼$18.22Volume175,282 shsAverage Volume380,419 shsMarket Capitalization$316.16 millionP/E RatioN/ADividend YieldN/APrice Target$11.81Consensus RatingModerate Buy Company Overview OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events. The company was founded in 2006 and is based in Waltham, Massachusetts. Read More OptimizeRx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks25th Percentile Overall ScoreOPRX MarketRank™: OptimizeRx scored higher than 25% of companies evaluated by MarketBeat, and ranked 566th out of 665 stocks in the computer and technology sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.4 / 5Analyst RatingModerate Buy Consensus RatingOptimizeRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 8 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageOptimizeRx has only been the subject of 3 research reports in the past 90 days.Read more about OptimizeRx's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for OptimizeRx are expected to grow in the coming year, from ($0.33) to ($0.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OptimizeRx is -31.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OptimizeRx is -31.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioOptimizeRx has a PEG Ratio of 2.40. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioOptimizeRx has a P/B Ratio of 2.65. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.81% of the float of OptimizeRx has been sold short.Short Interest Ratio / Days to CoverOptimizeRx has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in OptimizeRx has recently decreased by 0.87%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOptimizeRx does not currently pay a dividend.Dividend GrowthOptimizeRx does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.81% of the float of OptimizeRx has been sold short.Short Interest Ratio / Days to CoverOptimizeRx has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in OptimizeRx has recently decreased by 0.87%, indicating that investor sentiment is improving. News and Social Media3.1 / 5News Sentiment0.67 News SentimentOptimizeRx has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Computer and Technology companies.News Coverage This WeekMarketBeat has tracked 6 news articles for OptimizeRx this week, compared to 3 articles on an average week.Search Interest14 people have searched for OPRX on MarketBeat in the last 30 days. This is an increase of 56% compared to the previous 30 days.MarketBeat Follows13 people have added OptimizeRx to their MarketBeat watchlist in the last 30 days. This is an increase of 1,200% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, OptimizeRx insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.60% of the stock of OptimizeRx is held by insiders.Percentage Held by Institutions76.47% of the stock of OptimizeRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about OptimizeRx's insider trading history. Receive OPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OptimizeRx and its competitors with MarketBeat's FREE daily newsletter. Email Address OPRX Stock News HeadlinesOptimizeRx announces leadership team advancementsAugust 19 at 2:00 PM | msn.comOptimizeRx Announces Leadership Changes for Strategic GrowthAugust 19 at 2:00 PM | msn.comElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a new AI supercomputer—what one industry CEO calls “the most powerful in the world.” Musk says this tech will drive the next wave of American innovation. You can’t invest in the supercomputer directly—but there’s a backdoor way to access the company powering it. It’s smaller than Tesla or Nvidia, but both rely on it for future growth.August 22 at 2:00 AM | Paradigm Press (Ad)OptimizeRx Corp. Announces Leadership Changes to Enhance Growth Strategy and ProfitabilityAugust 19 at 8:11 AM | quiverquant.comQOptimizeRx Corporation Announces Leadership Team Advancements to Accelerate Strategic GrowthAugust 19 at 7:30 AM | globenewswire.comBrokerages Set OptimizeRx Corp. (NASDAQ:OPRX) Target Price at $11.81August 19 at 2:17 AM | americanbankingnews.comOptimizeRx (NASDAQ:OPRX) Price Target Raised to $20.00August 14, 2025 | americanbankingnews.comOptimizeRx Earnings Call: Strong Growth and Positive OutlookAugust 13, 2025 | msn.comSee More Headlines OPRX Stock Analysis - Frequently Asked Questions How have OPRX shares performed this year? OptimizeRx's stock was trading at $4.86 at the beginning of the year. Since then, OPRX stock has increased by 250.4% and is now trading at $17.03. How were OptimizeRx's earnings last quarter? OptimizeRx Corp. (NASDAQ:OPRX) announced its quarterly earnings data on Monday, May, 12th. The company reported $0.08 earnings per share for the quarter, beating analysts' consensus estimates of ($0.11) by $0.19. The company had revenue of $21.93 million for the quarter, compared to the consensus estimate of $18.69 million. OptimizeRx had a positive trailing twelve-month return on equity of 4.50% and a negative net margin of 9.42%. Read the conference call transcript. Who are OptimizeRx's major shareholders? OptimizeRx's top institutional shareholders include Blair William & Co. IL (3.40%), Kennedy Capital Management LLC (2.54%), Manatuck Hill Partners LLC (2.45%) and Geode Capital Management LLC (2.16%). Insiders that own company stock include William J Febbo, James Paul Lang and Marion Odence-Ford. View institutional ownership trends. How do I buy shares of OptimizeRx? Shares of OPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of OptimizeRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that OptimizeRx investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Intel (INTC). Company Calendar Last Earnings5/12/2025Today8/22/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorComputer and Technology Industry COMP - SOFTWARE Sub-IndustryBusiness Services Current SymbolNASDAQ:OPRX CIK1448431 Webwww.optimizerx.com Phone(248) 651-6568Fax248-453-5529Employees100Year FoundedN/APrice Target and Rating Average Price Target for OptimizeRx$11.81 High Price Target$20.00 Low Price Target$5.00 Potential Upside/Downside-30.6%Consensus RatingModerate Buy Rating Score (0-4)2.73 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($0.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth2.4Net Income-$18.66 million Net Margins-9.42% Pretax Margin-8.88% Return on Equity4.50% Return on Assets3.12% Debt Debt-to-Equity Ratio0.21 Current Ratio2.57 Quick Ratio2.57 Sales & Book Value Annual Sales$104.75 million Price / Sales3.02 Cash FlowN/A Price / Cash FlowN/A Book Value$6.43 per share Price / Book2.65Miscellaneous Outstanding Shares18,565,000Free Float17,525,000Market Cap$316.16 million OptionableOptionable Beta1.33 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:OPRX) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSilver’s Still Under $35… For Now.Silver is trading around $33—but insiders are betting on a $70 breakout by year’s end. With supply shrinkin...GoldenCrest Metals | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OptimizeRx Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share OptimizeRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.